Bausch + Lomb to Present Scientific Data and Analyses on Xipere at Macula Society Annual Meeting

Bausch + Lomb announced it will feature two podium presentations on Xipere during the Macula Society annual meeting, which will take place in Palm Springs, California, Feb. 7-10, 2024.

One presentation will highlight the results of a study assessing the durability of Xipere and subsequent patterns for treatment of uveitic macular edema in clinical practice. Another will include findings from a physician survey on the early adoption of Xipere in which retina and uveitis specialists shared their perspectives on early experiences with the suprachoroidal injection technique.

The featured studies include:

• “Durability and rescue therapy after suprachoroidal injection of triamcinolone acetonide injectable suspension for uveitic macular edema in clinical practice.” Singer et al.
• “Early Adoption of Triamcinolone Acetonide Suprachoroidal Injection for Uveitic Macular Edema: A Physician Survey.” Henry et al. 

Xipere is the first and only therapy available in the United States that utilizes the suprachoroidal space to treat patients suffering from macular edema associated with uveitis, according to Bausch + Lomb. It became commercially available in March 2022.